CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 63 enrolled
Drug / intervention
MK-8666 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01971554
NCT01971554Phase 1Completed
CompareCT.gov

A Multiple Dose Clinical Trial to Study the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of MK-8666 in Type 2 Diabetes Mellitus Patients

Merck Sharp & Dohme LLC·interventional·Posted Oct 29, 2013·Updated Sep 10, 2018

In Brief

A Phase 1 clinical trial evaluating MK-8666 and Placebo for Type 2 Diabetes Mellitus. Completed, enrolled 63 participants.

Detailed Summary

This is a study of the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of MK-8666 in participants with type 2 diabetes mellitus (T2DM). Participants enrolled in this trial would be either treatment-naive or have washed off of oral anti-hyperglycemic agents. MK-8666 is planned to be administered orally for up to 2 weeks. The primary hypothesis for this study is that after 14 days of once daily treatment with MK-8666, at a dose that is safe and well tolerated, the placebo-corrected fasting plasma glucose reduction from baseline is ≥34 mg/dL.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
Countries--
Collaborators--

Timeline

Phase 1CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedOct 29, 2013
Enrollment StartOct 14, 2013
Primary CompletionApr 26, 2014
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 12.7 years ago

Interventions

MK-8666drug

MK-8666, capsules, oral, QD, Days 1 to 14

Placebodrug

Placebo, capsules, oral, QD, Days 1 to 14